 Prem Subramanian
Concepts (478)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papilledema | 16 | 2023 | 39 | 6.400 |
Why?
| | Optic Disk | 17 | 2023 | 45 | 5.720 |
Why?
| | Pseudotumor Cerebri | 12 | 2024 | 28 | 5.080 |
Why?
| | Optic Nerve Diseases | 15 | 2023 | 39 | 4.260 |
Why?
| | Intracranial Hypertension | 8 | 2023 | 40 | 3.990 |
Why?
| | Optic Neuropathy, Ischemic | 10 | 2023 | 30 | 3.940 |
Why?
| | Tomography, Optical Coherence | 19 | 2023 | 213 | 3.400 |
Why?
| | Vision Disorders | 19 | 2023 | 142 | 3.370 |
Why?
| | Visual Fields | 19 | 2022 | 90 | 3.260 |
Why?
| | Ophthalmology | 9 | 2025 | 86 | 3.010 |
Why?
| | Oculomotor Nerve Diseases | 6 | 2025 | 10 | 2.920 |
Why?
| | Visual Acuity | 19 | 2025 | 356 | 2.850 |
Why?
| | Eye Injuries | 5 | 2025 | 45 | 2.440 |
Why?
| | Optic Neuritis | 8 | 2023 | 41 | 2.340 |
Why?
| | Abducens Nerve Diseases | 5 | 2022 | 12 | 2.320 |
Why?
| | Hemianopsia | 6 | 2022 | 9 | 2.180 |
Why?
| | Fluorescein Angiography | 10 | 2021 | 151 | 2.010 |
Why?
| | Exophthalmos | 5 | 2024 | 18 | 2.000 |
Why?
| | Graves Ophthalmopathy | 5 | 2024 | 10 | 1.910 |
Why?
| | Retinal Ganglion Cells | 10 | 2022 | 110 | 1.790 |
Why?
| | Carotid-Cavernous Sinus Fistula | 4 | 2021 | 9 | 1.790 |
Why?
| | Nerve Fibers | 9 | 2022 | 96 | 1.730 |
Why?
| | Eye Diseases, Hereditary | 3 | 2019 | 12 | 1.660 |
Why?
| | Embolization, Therapeutic | 5 | 2021 | 229 | 1.660 |
Why?
| | Retinal Artery Occlusion | 2 | 2022 | 9 | 1.530 |
Why?
| | Diplopia | 7 | 2024 | 19 | 1.510 |
Why?
| | Meningioma | 4 | 2023 | 91 | 1.470 |
Why?
| | Eye Diseases | 5 | 2025 | 87 | 1.410 |
Why?
| | Ocular Motility Disorders | 2 | 2023 | 27 | 1.360 |
Why?
| | Intraocular Pressure | 9 | 2022 | 307 | 1.320 |
Why?
| | Humans | 139 | 2025 | 137585 | 1.310 |
Why?
| | Isaacs Syndrome | 2 | 2023 | 5 | 1.260 |
Why?
| | Astronauts | 4 | 2023 | 27 | 1.210 |
Why?
| | Magnetic Resonance Imaging | 14 | 2025 | 3566 | 1.200 |
Why?
| | Perceptual Disorders | 2 | 2019 | 23 | 1.170 |
Why?
| | Orbit | 6 | 2023 | 70 | 1.160 |
Why?
| | Retina | 5 | 2022 | 298 | 1.130 |
Why?
| | Optic Nerve | 6 | 2023 | 64 | 1.110 |
Why?
| | Space Flight | 4 | 2023 | 87 | 1.060 |
Why?
| | Orbital Diseases | 4 | 2013 | 32 | 1.060 |
Why?
| | Optic Disk Drusen | 4 | 2020 | 6 | 1.040 |
Why?
| | Color Vision Defects | 2 | 2017 | 8 | 1.020 |
Why?
| | Multiple Sclerosis | 3 | 2018 | 455 | 0.980 |
Why?
| | Trochlear Nerve Diseases | 3 | 2023 | 7 | 0.980 |
Why?
| | Neurology | 4 | 2021 | 113 | 0.970 |
Why?
| | Ophthalmic Artery | 3 | 2021 | 5 | 0.930 |
Why?
| | Orbital Neoplasms | 2 | 2018 | 24 | 0.930 |
Why?
| | Academies and Institutes | 2 | 2024 | 53 | 0.910 |
Why?
| | Eye | 3 | 2021 | 108 | 0.870 |
Why?
| | Glaucoma | 6 | 2023 | 237 | 0.850 |
Why?
| | Teratoma | 1 | 2025 | 114 | 0.850 |
Why?
| | Rhabdoid Tumor | 1 | 2025 | 99 | 0.840 |
Why?
| | Stroke | 3 | 2017 | 1120 | 0.820 |
Why?
| | Visual Field Tests | 9 | 2020 | 16 | 0.810 |
Why?
| | Optic Atrophy, Hereditary, Leber | 4 | 2024 | 5 | 0.800 |
Why?
| | Intracranial Aneurysm | 2 | 2022 | 97 | 0.790 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2018 | 58 | 0.790 |
Why?
| | Orbital Pseudotumor | 2 | 2018 | 2 | 0.790 |
Why?
| | Neuroimaging | 2 | 2024 | 259 | 0.770 |
Why?
| | Intracranial Pressure | 5 | 2023 | 49 | 0.760 |
Why?
| | Absorption, Physiological | 1 | 2021 | 4 | 0.760 |
Why?
| | Embolism | 1 | 2022 | 41 | 0.750 |
Why?
| | Prostaglandins, Synthetic | 1 | 2021 | 5 | 0.750 |
Why?
| | Myofibroma | 1 | 2021 | 4 | 0.750 |
Why?
| | Adie Syndrome | 1 | 2021 | 2 | 0.730 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 132 | 0.720 |
Why?
| | Cerebral Small Vessel Diseases | 1 | 2021 | 5 | 0.720 |
Why?
| | Cerebrospinal Fluid | 1 | 2021 | 92 | 0.720 |
Why?
| | Nasal Mucosa | 1 | 2021 | 107 | 0.710 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.700 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.700 |
Why?
| | Recreation | 1 | 2021 | 23 | 0.700 |
Why?
| | Meningeal Neoplasms | 3 | 2023 | 100 | 0.700 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.700 |
Why?
| | Disease Management | 3 | 2016 | 628 | 0.690 |
Why?
| | Hallucinations | 1 | 2020 | 29 | 0.680 |
Why?
| | Societies, Medical | 2 | 2024 | 820 | 0.680 |
Why?
| | Adult | 41 | 2025 | 37929 | 0.670 |
Why?
| | Arteriovenous Malformations | 2 | 2011 | 27 | 0.660 |
Why?
| | Glaucoma, Open-Angle | 2 | 2020 | 103 | 0.660 |
Why?
| | Virtual Reality | 1 | 2021 | 61 | 0.660 |
Why?
| | Peripheral Nerves | 2 | 2020 | 65 | 0.650 |
Why?
| | Male | 54 | 2025 | 67762 | 0.650 |
Why?
| | Retinopathy of Prematurity | 4 | 2023 | 142 | 0.640 |
Why?
| | Choroid | 1 | 2020 | 62 | 0.640 |
Why?
| | Macula Lutea | 2 | 2019 | 21 | 0.630 |
Why?
| | Middle Aged | 41 | 2025 | 33479 | 0.620 |
Why?
| | Regional Blood Flow | 1 | 2021 | 474 | 0.610 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 243 | 0.610 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 85 | 0.610 |
Why?
| | Vertigo | 1 | 2019 | 39 | 0.600 |
Why?
| | Optic Nerve Neoplasms | 3 | 2023 | 11 | 0.600 |
Why?
| | Optic Chiasm | 5 | 2021 | 18 | 0.600 |
Why?
| | Female | 53 | 2025 | 73304 | 0.600 |
Why?
| | Sinus Thrombosis, Intracranial | 2 | 2020 | 21 | 0.580 |
Why?
| | Sphenoid Sinus | 1 | 2017 | 11 | 0.570 |
Why?
| | Paranasal Sinus Diseases | 1 | 2017 | 15 | 0.560 |
Why?
| | Reimbursement Mechanisms | 1 | 2018 | 85 | 0.540 |
Why?
| | Cranial Sinuses | 2 | 2014 | 15 | 0.540 |
Why?
| | Contrast Sensitivity | 2 | 2015 | 14 | 0.530 |
Why?
| | Giant Cell Arteritis | 4 | 2022 | 49 | 0.530 |
Why?
| | Postural Balance | 1 | 2019 | 215 | 0.500 |
Why?
| | Visual Pathways | 2 | 2013 | 55 | 0.500 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2021 | 40 | 0.480 |
Why?
| | Aged | 24 | 2025 | 23961 | 0.480 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.480 |
Why?
| | Color Vision | 1 | 2015 | 3 | 0.480 |
Why?
| | Tomography, X-Ray Computed | 3 | 2024 | 2691 | 0.480 |
Why?
| | Arteriovenous Fistula | 2 | 2006 | 36 | 0.480 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2015 | 30 | 0.480 |
Why?
| | Carotid Artery, Internal | 3 | 2021 | 42 | 0.470 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 62 | 0.460 |
Why?
| | Nervous System Diseases | 3 | 2020 | 266 | 0.460 |
Why?
| | Tuberculosis, Lymph Node | 1 | 2014 | 7 | 0.460 |
Why?
| | Tuberculosis, Ocular | 1 | 2014 | 8 | 0.460 |
Why?
| | Keratoconjunctivitis | 1 | 2014 | 6 | 0.460 |
Why?
| | Recovery of Function | 2 | 2017 | 653 | 0.460 |
Why?
| | Aspergillosis | 2 | 2013 | 21 | 0.450 |
Why?
| | Blindness | 2 | 2015 | 38 | 0.450 |
Why?
| | Cerebrovascular Disorders | 2 | 2013 | 96 | 0.450 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 683 | 0.440 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 606 | 0.440 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2014 | 36 | 0.440 |
Why?
| | Young Adult | 19 | 2025 | 13209 | 0.430 |
Why?
| | Headache | 5 | 2021 | 147 | 0.420 |
Why?
| | Circle of Willis | 1 | 2013 | 7 | 0.420 |
Why?
| | Medical Audit | 1 | 2013 | 78 | 0.420 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 49 | 0.420 |
Why?
| | Decompression, Surgical | 1 | 2014 | 106 | 0.420 |
Why?
| | Brain Injuries, Traumatic | 1 | 2018 | 360 | 0.410 |
Why?
| | Ischemic Attack, Transient | 1 | 2013 | 65 | 0.400 |
Why?
| | Ophthalmologists | 2 | 2024 | 12 | 0.390 |
Why?
| | Ubiquinone | 2 | 2024 | 29 | 0.390 |
Why?
| | Cerebral Angiography | 4 | 2021 | 109 | 0.390 |
Why?
| | Medicare | 1 | 2018 | 773 | 0.380 |
Why?
| | Skin Neoplasms | 1 | 2020 | 855 | 0.380 |
Why?
| | Referral and Consultation | 1 | 2018 | 786 | 0.380 |
Why?
| | Retrospective Studies | 19 | 2023 | 15657 | 0.380 |
Why?
| | Lymphangioma | 1 | 2011 | 7 | 0.370 |
Why?
| | Varicose Veins | 1 | 2011 | 17 | 0.370 |
Why?
| | Congresses as Topic | 2 | 2025 | 233 | 0.370 |
Why?
| | Brain | 4 | 2024 | 2668 | 0.360 |
Why?
| | Diagnosis, Differential | 4 | 2023 | 1483 | 0.360 |
Why?
| | ROC Curve | 7 | 2021 | 554 | 0.360 |
Why?
| | Follow-Up Studies | 8 | 2024 | 5131 | 0.350 |
Why?
| | Eye Infections, Fungal | 1 | 2010 | 7 | 0.350 |
Why?
| | Oculomotor Muscles | 2 | 2023 | 40 | 0.350 |
Why?
| | Aspergillus fumigatus | 1 | 2010 | 26 | 0.340 |
Why?
| | Brain Diseases | 1 | 2011 | 141 | 0.330 |
Why?
| | Cross-Sectional Studies | 8 | 2025 | 5472 | 0.330 |
Why?
| | Military Medicine | 2 | 2008 | 63 | 0.330 |
Why?
| | Algorithms | 6 | 2023 | 1704 | 0.320 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1313 | 0.300 |
Why?
| | Retinal Vein | 1 | 2008 | 13 | 0.300 |
Why?
| | Cerebrospinal Fluid Proteins | 1 | 2008 | 8 | 0.300 |
Why?
| | Strabismus | 1 | 2008 | 29 | 0.290 |
Why?
| | United States | 10 | 2024 | 14841 | 0.290 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1040 | 0.280 |
Why?
| | Iraq War, 2003-2011 | 1 | 2008 | 127 | 0.280 |
Why?
| | Eye Movements | 2 | 2018 | 67 | 0.280 |
Why?
| | Corneal Edema | 1 | 2007 | 4 | 0.270 |
Why?
| | Eye Pain | 2 | 2017 | 7 | 0.270 |
Why?
| | Ophthalmoplegia, Chronic Progressive External | 1 | 2007 | 3 | 0.270 |
Why?
| | Mitochondrial Myopathies | 1 | 2007 | 9 | 0.270 |
Why?
| | Prostatectomy | 1 | 2007 | 104 | 0.270 |
Why?
| | Postoperative Complications | 3 | 2013 | 2654 | 0.270 |
Why?
| | Decision Making | 1 | 2014 | 900 | 0.270 |
Why?
| | Astigmatism | 2 | 2006 | 10 | 0.270 |
Why?
| | Photorefractive Keratectomy | 2 | 2006 | 19 | 0.260 |
Why?
| | Septo-Optic Dysplasia | 1 | 2006 | 4 | 0.260 |
Why?
| | Stents | 3 | 2016 | 527 | 0.260 |
Why?
| | Temporal Arteries | 3 | 2022 | 45 | 0.260 |
Why?
| | Craniocerebral Trauma | 1 | 2008 | 170 | 0.250 |
Why?
| | Visual Cortex | 1 | 2006 | 70 | 0.250 |
Why?
| | Pandemics | 3 | 2025 | 1639 | 0.240 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 242 | 0.240 |
Why?
| | Cavernous Sinus | 2 | 2021 | 19 | 0.240 |
Why?
| | Pupil | 1 | 2025 | 18 | 0.240 |
Why?
| | Ophthalmoscopy | 3 | 2021 | 36 | 0.240 |
Why?
| | Carotid Artery Diseases | 1 | 2005 | 64 | 0.240 |
Why?
| | Adolescent | 13 | 2025 | 21513 | 0.240 |
Why?
| | Transverse Sinuses | 2 | 2016 | 8 | 0.240 |
Why?
| | Prospective Studies | 9 | 2019 | 7604 | 0.230 |
Why?
| | Ocular Hypertension | 3 | 2015 | 69 | 0.230 |
Why?
| | Marijuana Smoking | 2 | 2025 | 252 | 0.230 |
Why?
| | Retinal Artery | 1 | 2004 | 17 | 0.230 |
Why?
| | Sensitivity and Specificity | 6 | 2025 | 1946 | 0.230 |
Why?
| | Retinitis | 1 | 2004 | 20 | 0.230 |
Why?
| | Retinal Vasculitis | 1 | 2004 | 10 | 0.220 |
Why?
| | Peptide Hormones | 1 | 2004 | 11 | 0.220 |
Why?
| | Craniotomy | 1 | 2025 | 77 | 0.220 |
Why?
| | Aneurysm | 1 | 2004 | 31 | 0.220 |
Why?
| | Fatal Outcome | 1 | 2025 | 303 | 0.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2024 | 804 | 0.220 |
Why?
| | Artificial Intelligence | 3 | 2023 | 279 | 0.210 |
Why?
| | Eyelids | 1 | 2024 | 37 | 0.210 |
Why?
| | Laser Coagulation | 2 | 2019 | 68 | 0.210 |
Why?
| | Eyeglasses | 1 | 2003 | 7 | 0.210 |
Why?
| | Ultrasonography | 2 | 2021 | 759 | 0.200 |
Why?
| | Parvovirinae | 1 | 2022 | 3 | 0.200 |
Why?
| | Diphosphonates | 1 | 2003 | 66 | 0.200 |
Why?
| | Substance Abuse Detection | 1 | 2024 | 87 | 0.200 |
Why?
| | Eye Burns | 1 | 2022 | 12 | 0.200 |
Why?
| | Telemedicine | 2 | 2023 | 862 | 0.200 |
Why?
| | Physicians | 2 | 2022 | 910 | 0.200 |
Why?
| | Radiation Injuries | 1 | 2004 | 145 | 0.200 |
Why?
| | Paralysis | 1 | 2023 | 71 | 0.200 |
Why?
| | Eyelid Diseases | 1 | 2022 | 19 | 0.200 |
Why?
| | Arteries | 2 | 2021 | 269 | 0.200 |
Why?
| | Myopia | 1 | 2003 | 47 | 0.200 |
Why?
| | Compartment Syndromes | 1 | 2022 | 25 | 0.200 |
Why?
| | Fluorometry | 1 | 2021 | 17 | 0.190 |
Why?
| | Oculomotor Nerve | 1 | 2021 | 5 | 0.190 |
Why?
| | Hallucinogens | 1 | 2024 | 105 | 0.190 |
Why?
| | Cornea | 1 | 2003 | 138 | 0.190 |
Why?
| | Dinoprost | 1 | 2021 | 44 | 0.190 |
Why?
| | Fundus Oculi | 2 | 2020 | 65 | 0.190 |
Why?
| | Weight Loss | 2 | 2024 | 787 | 0.180 |
Why?
| | Administration, Intranasal | 1 | 2021 | 90 | 0.180 |
Why?
| | Skull Base | 1 | 2021 | 53 | 0.180 |
Why?
| | Endovascular Procedures | 2 | 2018 | 312 | 0.180 |
Why?
| | Particulate Matter | 1 | 2024 | 315 | 0.180 |
Why?
| | Treatment Outcome | 9 | 2024 | 10811 | 0.180 |
Why?
| | Retinal Vessels | 1 | 2021 | 69 | 0.180 |
Why?
| | Blood Pressure | 1 | 2008 | 1786 | 0.180 |
Why?
| | Wounds and Injuries | 1 | 2008 | 758 | 0.180 |
Why?
| | Cannabis | 2 | 2025 | 494 | 0.180 |
Why?
| | Dissent and Disputes | 1 | 2021 | 20 | 0.180 |
Why?
| | Child | 9 | 2025 | 21935 | 0.180 |
Why?
| | Marijuana Abuse | 1 | 2024 | 233 | 0.180 |
Why?
| | Posture | 2 | 2019 | 185 | 0.170 |
Why?
| | Lewy Bodies | 1 | 2020 | 10 | 0.170 |
Why?
| | Bone Neoplasms | 1 | 2003 | 247 | 0.170 |
Why?
| | Crowding | 1 | 2021 | 35 | 0.170 |
Why?
| | Aged, 80 and over | 5 | 2017 | 7635 | 0.170 |
Why?
| | Antigens, Viral | 1 | 2021 | 178 | 0.170 |
Why?
| | Bariatric Surgery | 1 | 2024 | 217 | 0.170 |
Why?
| | Vision, Ocular | 1 | 2020 | 37 | 0.170 |
Why?
| | Risk Factors | 7 | 2025 | 10388 | 0.170 |
Why?
| | Macular Degeneration | 1 | 2022 | 164 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 135 | 0.160 |
Why?
| | Fluorescent Dyes | 1 | 2021 | 321 | 0.160 |
Why?
| | Prostatic Neoplasms | 2 | 2007 | 1043 | 0.160 |
Why?
| | Fovea Centralis | 1 | 2019 | 11 | 0.160 |
Why?
| | Drug Therapy, Combination | 2 | 2014 | 1066 | 0.160 |
Why?
| | DNA, Viral | 1 | 2021 | 364 | 0.160 |
Why?
| | Air Pollutants | 1 | 2024 | 430 | 0.160 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 197 | 0.150 |
Why?
| | Microvessels | 1 | 2020 | 88 | 0.150 |
Why?
| | Health Surveys | 1 | 2021 | 514 | 0.150 |
Why?
| | Retinal Detachment | 1 | 2019 | 63 | 0.150 |
Why?
| | Ligation | 1 | 2018 | 92 | 0.150 |
Why?
| | Inflammation | 4 | 2023 | 2837 | 0.150 |
Why?
| | Dizziness | 1 | 2019 | 82 | 0.150 |
Why?
| | Tonometry, Ocular | 3 | 2019 | 97 | 0.150 |
Why?
| | Skull Base Neoplasms | 1 | 2018 | 30 | 0.140 |
Why?
| | Forms and Records Control | 1 | 2018 | 23 | 0.140 |
Why?
| | Healthy Volunteers | 1 | 2019 | 199 | 0.140 |
Why?
| | Gestational Age | 4 | 2023 | 910 | 0.140 |
Why?
| | Infant | 6 | 2025 | 9465 | 0.140 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2017 | 3 | 0.140 |
Why?
| | Herpesvirus 3, Human | 1 | 2021 | 332 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 229 | 0.140 |
Why?
| | Periodicals as Topic | 1 | 2020 | 211 | 0.140 |
Why?
| | Quality of Life | 4 | 2022 | 2892 | 0.140 |
Why?
| | Capillaries | 1 | 2018 | 108 | 0.140 |
Why?
| | Headache Disorders | 1 | 2017 | 18 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.140 |
Why?
| | Social Media | 1 | 2020 | 158 | 0.140 |
Why?
| | Child, Preschool | 3 | 2025 | 11074 | 0.130 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 1997 | 25 | 0.130 |
Why?
| | X Chromosome | 1 | 1997 | 53 | 0.130 |
Why?
| | Disease Progression | 3 | 2020 | 2757 | 0.130 |
Why?
| | Accidents, Traffic | 1 | 2018 | 190 | 0.130 |
Why?
| | Arteritis | 1 | 2016 | 28 | 0.130 |
Why?
| | Area Under Curve | 2 | 2014 | 314 | 0.130 |
Why?
| | Prevalence | 2 | 2016 | 2734 | 0.130 |
Why?
| | Animals | 6 | 2024 | 36940 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3284 | 0.130 |
Why?
| | Abducens Nerve | 1 | 2015 | 3 | 0.120 |
Why?
| | Constriction, Pathologic | 2 | 2014 | 245 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 486 | 0.120 |
Why?
| | Neuronal Plasticity | 2 | 2017 | 290 | 0.120 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 752 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 442 | 0.120 |
Why?
| | Activities of Daily Living | 1 | 2019 | 413 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
| | Autoantibodies | 1 | 2023 | 1496 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.120 |
Why?
| | Lateral Sinus Thrombosis | 1 | 2015 | 1 | 0.120 |
Why?
| | DNA Replication | 1 | 1997 | 238 | 0.120 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 263 | 0.120 |
Why?
| | Pyrazinamide | 1 | 2014 | 12 | 0.120 |
Why?
| | Blood Sedimentation | 1 | 2014 | 39 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 1060 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 493 | 0.110 |
Why?
| | Ethambutol | 1 | 2014 | 26 | 0.110 |
Why?
| | Melanoma | 1 | 2021 | 760 | 0.110 |
Why?
| | Health Policy | 1 | 2018 | 388 | 0.110 |
Why?
| | Isoniazid | 1 | 2014 | 63 | 0.110 |
Why?
| | Rifampin | 1 | 2014 | 84 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2016 | 3556 | 0.110 |
Why?
| | Syndrome | 3 | 2019 | 358 | 0.110 |
Why?
| | Carbamazepine | 1 | 2013 | 20 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1587 | 0.100 |
Why?
| | Incidence | 3 | 2022 | 2804 | 0.100 |
Why?
| | Antitubercular Agents | 1 | 2014 | 206 | 0.100 |
Why?
| | Abscess | 1 | 2013 | 75 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2828 | 0.100 |
Why?
| | Cognition | 1 | 2020 | 1153 | 0.100 |
Why?
| | Dependovirus | 2 | 2023 | 68 | 0.100 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2012 | 13 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2129 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 580 | 0.090 |
Why?
| | Vision, Binocular | 1 | 2011 | 21 | 0.090 |
Why?
| | Hemodynamics | 1 | 2016 | 1113 | 0.090 |
Why?
| | Anticonvulsants | 1 | 2013 | 217 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2014 | 2031 | 0.090 |
Why?
| | DNA Transposable Elements | 1 | 1992 | 121 | 0.090 |
Why?
| | Penicillin G Benzathine | 1 | 2010 | 1 | 0.090 |
Why?
| | Neonatal Screening | 2 | 2023 | 169 | 0.090 |
Why?
| | Syphilis Serodiagnosis | 1 | 2010 | 4 | 0.090 |
Why?
| | Penicillin G | 1 | 2010 | 7 | 0.090 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5757 | 0.090 |
Why?
| | Genetic Therapy | 2 | 2023 | 297 | 0.090 |
Why?
| | Obesity | 1 | 2004 | 2992 | 0.090 |
Why?
| | Psychology | 1 | 2011 | 85 | 0.090 |
Why?
| | Military Personnel | 2 | 2008 | 544 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1236 | 0.080 |
Why?
| | Histoplasmosis | 1 | 2010 | 17 | 0.080 |
Why?
| | India | 2 | 2021 | 195 | 0.080 |
Why?
| | Infant, Newborn | 4 | 2023 | 6079 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2010 | 141 | 0.080 |
Why?
| | Time Factors | 5 | 2020 | 6828 | 0.080 |
Why?
| | Venous Pressure | 1 | 2008 | 8 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1062 | 0.070 |
Why?
| | Antioxidants | 2 | 2024 | 584 | 0.070 |
Why?
| | Iraq | 1 | 2008 | 53 | 0.070 |
Why?
| | Afghanistan | 1 | 2008 | 71 | 0.070 |
Why?
| | Birth Weight | 2 | 2023 | 516 | 0.070 |
Why?
| | Escherichia coli | 1 | 1992 | 815 | 0.070 |
Why?
| | Cohort Studies | 2 | 2016 | 5742 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4295 | 0.070 |
Why?
| | Lasers, Excimer | 2 | 2006 | 28 | 0.070 |
Why?
| | Darkness | 1 | 2006 | 28 | 0.060 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2006 | 21 | 0.060 |
Why?
| | Functional Laterality | 1 | 2006 | 223 | 0.060 |
Why?
| | Maxillary Artery | 1 | 2005 | 3 | 0.060 |
Why?
| | Developed Countries | 1 | 2025 | 39 | 0.060 |
Why?
| | Angiography, Digital Subtraction | 1 | 2005 | 44 | 0.060 |
Why?
| | Growth Cones | 1 | 2004 | 7 | 0.060 |
Why?
| | Bucladesine | 1 | 2004 | 26 | 0.060 |
Why?
| | Prognosis | 1 | 2013 | 4030 | 0.060 |
Why?
| | Retinal Hemorrhage | 1 | 2004 | 19 | 0.060 |
Why?
| | Platinum | 1 | 2005 | 50 | 0.060 |
Why?
| | Veins | 1 | 2005 | 63 | 0.060 |
Why?
| | Body Constitution | 1 | 2004 | 55 | 0.060 |
Why?
| | Ghrelin | 1 | 2004 | 36 | 0.060 |
Why?
| | Mice | 1 | 2021 | 17787 | 0.060 |
Why?
| | Ganglia, Spinal | 1 | 2004 | 77 | 0.060 |
Why?
| | Nerve Regeneration | 1 | 2004 | 59 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2024 | 65 | 0.050 |
Why?
| | Growth Hormone | 1 | 2004 | 101 | 0.050 |
Why?
| | Stereotaxic Techniques | 1 | 2004 | 39 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2013 | 1238 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2025 | 688 | 0.050 |
Why?
| | Tremor | 1 | 2024 | 65 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 280 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2006 | 309 | 0.050 |
Why?
| | Tubulin | 1 | 2004 | 144 | 0.050 |
Why?
| | Equipment Design | 1 | 2005 | 522 | 0.050 |
Why?
| | Demography | 1 | 2024 | 291 | 0.050 |
Why?
| | Particle Size | 1 | 2024 | 394 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2005 | 240 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 236 | 0.050 |
Why?
| | Angiography | 1 | 2023 | 207 | 0.050 |
Why?
| | Prednisone | 1 | 2003 | 240 | 0.050 |
Why?
| | Mutation | 2 | 2024 | 3958 | 0.050 |
Why?
| | Baltimore | 2 | 2012 | 60 | 0.050 |
Why?
| | Methylprednisolone | 1 | 2022 | 86 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 683 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 200 | 0.050 |
Why?
| | Global Health | 1 | 2025 | 386 | 0.050 |
Why?
| | Tissue Fixation | 1 | 2021 | 36 | 0.050 |
Why?
| | Paraffin Embedding | 1 | 2021 | 32 | 0.050 |
Why?
| | Environmental Monitoring | 1 | 2024 | 370 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2022 | 319 | 0.040 |
Why?
| | Formaldehyde | 1 | 2021 | 63 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2023 | 405 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 99 | 0.040 |
Why?
| | Hospital Units | 1 | 2021 | 29 | 0.040 |
Why?
| | Spinal Cord Injuries | 1 | 2004 | 212 | 0.040 |
Why?
| | Safety | 1 | 2003 | 338 | 0.040 |
Why?
| | Cell Survival | 1 | 2024 | 1120 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1060 | 0.040 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 23 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1809 | 0.040 |
Why?
| | Light | 1 | 2003 | 381 | 0.040 |
Why?
| | Firearms | 1 | 2006 | 386 | 0.040 |
Why?
| | Tertiary Prevention | 1 | 2019 | 3 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2019 | 15 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 496 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 98 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 217 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 249 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2019 | 56 | 0.040 |
Why?
| | Extraterrestrial Environment | 1 | 2019 | 14 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2012 | 512 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1993 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5778 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 452 | 0.040 |
Why?
| | Linear Models | 1 | 2021 | 849 | 0.040 |
Why?
| | Gravity, Altered | 1 | 2018 | 7 | 0.040 |
Why?
| | Centrifugation | 1 | 2018 | 30 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2019 | 233 | 0.040 |
Why?
| | Rotation | 1 | 2018 | 117 | 0.040 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 101 | 0.040 |
Why?
| | Primary Prevention | 1 | 2019 | 196 | 0.030 |
Why?
| | Acetazolamide | 1 | 2017 | 26 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 916 | 0.030 |
Why?
| | Hybrid Cells | 1 | 1997 | 49 | 0.030 |
Why?
| | Diuretics | 1 | 2017 | 74 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 1997 | 145 | 0.030 |
Why?
| | Cricetinae | 1 | 1997 | 289 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 545 | 0.030 |
Why?
| | Oxygen | 1 | 2021 | 931 | 0.030 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 117 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1997 | 534 | 0.030 |
Why?
| | Azacitidine | 1 | 1997 | 140 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 290 | 0.030 |
Why?
| | Body Mass Index | 1 | 2004 | 2389 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 356 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 375 | 0.030 |
Why?
| | Analgesics | 1 | 2017 | 206 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 890 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1997 | 810 | 0.030 |
Why?
| | Vision Tests | 1 | 2015 | 17 | 0.030 |
Why?
| | Infant, Premature | 1 | 2019 | 574 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1774 | 0.030 |
Why?
| | Heart Rate | 1 | 2018 | 822 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 115 | 0.030 |
Why?
| | Tinnitus | 1 | 2015 | 57 | 0.030 |
Why?
| | Itraconazole | 1 | 2013 | 6 | 0.030 |
Why?
| | Immunocompetence | 1 | 2013 | 42 | 0.030 |
Why?
| | Voriconazole | 1 | 2013 | 20 | 0.030 |
Why?
| | Insulin | 1 | 2004 | 2409 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1381 | 0.030 |
Why?
| | Debridement | 1 | 2013 | 81 | 0.030 |
Why?
| | Chromatin | 1 | 1997 | 519 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2013 | 136 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2607 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1622 | 0.020 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 106 | 0.020 |
Why?
| | Triazoles | 1 | 2013 | 147 | 0.020 |
Why?
| | DNA Probes | 1 | 1992 | 60 | 0.020 |
Why?
| | Mutagenesis, Insertional | 1 | 1992 | 65 | 0.020 |
Why?
| | Neurosurgery | 1 | 2012 | 39 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1992 | 180 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2013 | 227 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 1992 | 399 | 0.020 |
Why?
| | History, 20th Century | 1 | 2012 | 325 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1992 | 523 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 1992 | 337 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 1007 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 470 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1738 | 0.020 |
Why?
| | Base Sequence | 1 | 1992 | 2181 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1992 | 2900 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 698 | 0.020 |
Why?
| | Postoperative Period | 1 | 2006 | 342 | 0.010 |
Why?
| | Tissue Transplantation | 1 | 2004 | 10 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2004 | 43 | 0.010 |
Why?
| | Axonal Transport | 1 | 2004 | 27 | 0.010 |
Why?
| | Visual Perception | 1 | 2006 | 160 | 0.010 |
Why?
| | Hypertension | 1 | 2013 | 1295 | 0.010 |
Why?
| | Up-Regulation | 1 | 2004 | 843 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2486 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5647 | 0.010 |
Why?
|
|
Subramanian's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|